Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
MWN-AI** Summary
Arvinas, Inc. (Nasdaq: ARVN), a pioneering biotechnology company focusing on targeted protein degradation therapies, is set to present Phase 1 clinical trial data for its investigational drug ARV-102 at the upcoming 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark. Scheduled for March 18, 2026, the presentation will provide crucial insights into the safety, pharmacokinetics, and pharmacodynamics of ARV-102 in patients with Parkinson's disease (PD).
ARV-102 is designed as an orally bioavailable PROTAC (PROteolysis TArgeting Chimera) that targets leucine-rich repeat kinase 2 (LRRK2), a protein linked to the pathogenesis of both PD and progressive supranuclear palsy (PSP), thereby addressing significant unmet medical needs in neurodegenerative disorders. This drug's ability to penetrate the blood-brain barrier allows it to specifically degrade LRRK2, which has shown increased activity and overexpression in affected patients.
The presentation, part of a symposium titled "Modulating Neuroinflammation, ?-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data," will discuss the early findings from the trial that highlight the drug's potential therapeutic benefits. Alongside this, Arvinas aims to commence a Phase 1b trial for ARV-102 in PSP patients, pending regulatory feedback, later in 2026.
Founded to tackle debilitating conditions through innovative solutions, Arvinas continues to advance its pipeline, which includes other investigational therapies targeting various cancers and diseases. These developments signal the company's commitment to leveraging its PROTAC platform for transformative treatments. For ongoing updates, stakeholders can visit Arvinas' website and follow their channels on LinkedIn and X.
MWN-AI** Analysis
As Arvinas, Inc. prepares to present Phase 1 clinical trial data for ARV-102 at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases, investors should closely monitor the implications of this presentation on the company’s stock performance. ARV-102, a novel PROTAC LRRK2 degrader targeting Parkinson's disease, represents a pivotal advancement in biotechnology’s fight against neurodegenerative disorders.
The upcoming presentation, scheduled for March 18, 2026, will unveil critical safety, pharmacokinetic, and pharmacodynamic data. Positive outcomes in these areas are crucial; they would likely bolster investor confidence and could attract additional institutional interest. Given the increasing prevalence of Parkinson’s disease globally, effective treatments like ARV-102 have significant market potential. Investors should consider the current market sentiment around neurodegenerative drugs, where the urgency for innovative therapies is high, potentially boosting demand for Arvinas’ offerings.
Moreover, the company’s ambitious plan to initiate a Phase 1b trial for progressive supranuclear palsy (PSP) could expand its market scope and diversify risk across neurodegenerative conditions. However, caution is warranted as clinical trials can be unpredictable, and stock volatility often accompanies such data releases. Investors should brace for potential volatility, particularly if results deviate from expectations.
Given the importance of effective communication during the presentation, Arvinas should emphasize any positive data trends, particularly concerning the drug's ability to cross the blood-brain barrier and its mechanism targeting LRRK2. This information could catalyze a favorable reaction in the stock.
In summary, while Arvinas presents a promising opportunity in a high-stakes market, investors should weigh potential gains against inherent risks, especially related to clinical outcomes and market responsiveness post-presentation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease –
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease (PD) will be presented at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in PD and progressive supranuclear palsy (PSP).
Presentation details are as follows:
Presentation Title: Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants with Parkinson’s Disease
Session Title: Modulating Neuroinflammation, ?-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data
Session Type: Symposium
Session Location: Hall 180-181
Date: March 18, 2026
Lecture Time: 3:30-3:45 PM CET
The full abstract can be accessed via the AD/PD™ 2026 interactive program.
About ARV-102
ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain scaffolding kinase with GTPase activity. Increased activity and overexpression of LRRK2 have been implicated in the pathogenesis of neurological diseases, including Parkinson’s disease and progressive supranuclear palsy (PSP). ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson’s disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the first half of 2026.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-102, including its degradation of leucine-rich repeat kinase 2, and potential future benefit to patients; and Arvinas’ plans with respect to ARV-102, including, pending regulatory feedback, the initiation of a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy, and the timing thereof. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “ability,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “potential,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
kirsten.owens@arvinas.com
FAQ**
What specific safety findings from the Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease will Arvinas Inc. (ARVN) emphasize during the presentation at the AD/PD™ 2026 conference?
How do the pharmacokinetic profiles of ARV-102 compare to existing therapies in the treatment of Parkinson’s disease, according to Arvinas Inc. (ARVN)?
Can Arvinas Inc. (ARVN) provide insights into the pharmacodynamic effects observed with multiple doses of ARV-102, particularly regarding LRRK2 modulation in Parkinson’s disease?
What are Arvinas Inc. (ARVN)'s next steps following the Phase 1 trial results, and how might they impact the planned Phase 1b trial in patients with progressive supranuclear palsy?
**MWN-AI FAQ is based on asking OpenAI questions about Arvinas Inc. (NASDAQ: ARVN).
NASDAQ: ARVN
ARVN Trading
-2.65% G/L:
$12.115 Last:
236,120 Volume:
$12.38 Open:
